EichorEICHOR
Study identifier: NCT04340076 Synced from ClinicalTrials.gov · August 05, 2026
● Completed

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Condition: Psoriasis · Psoriasis Vulgaris  ·  Sponsor: Radboud University Medical Center

PhasePhase 4
Planned participants244
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The main objective of this study is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care in psoriasis patients. Therefore, a pragmatic, multicentre, randomized, controlled, non-inferiority study will be carried out.

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Locations (19)

ULB ErasmeBrussels, Belgium
Ghent University HospitalGhent, Belgium
AZ Maria MiddelaresGhent, Belgium
AZ St LucasGhent, Belgium
UCL Saint LucLeuven, Belgium
UZ LeuvenLeuven, Belgium
CHU LiegeLiège, Belgium
Dermatologie MaldegemMaldegem, Belgium
Ziekenhuisgroep TwenteAlmelo, Netherlands
Bravis hospitalBergen op Zoom, Netherlands
Amphia HospitalBreda, Netherlands
Slingeland hospitalDoetinchem, Netherlands

+ 7 more locations — full list on the registry record.

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →